No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VNDA240517P7000
- 2.55
- 0.000.00%
15min DelayTrading Apr 25 12:01 ET
0.00High0.00Low
0.00Open2.55Pre Close0 Volume7 Open Interest7.00Strike Price0.00Turnover0.00%IV3.97%PremiumMay 17, 2024Expiry Date1.83Intrinsic Value100Multiplier8DDays to Expiry0.72Time Value100Contract SizeAmericanOptions Type--Delta--Gamma3.18Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Earnings Call Summary | Vanda Pharmaceuticals(VNDA.US) Q1 2024 Earnings Conference
The following is a summary of the Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript:Financial Performance:Vanda Pharmaceuticals posted total revenues of $47.5 million for Q1 2024, re
Vanda Pharmaceuticals | 10-Q: Quarterly report
Q1 2024 Vanda Pharmaceuticals Inc Earnings Call
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Other Big Stocks Moving Lower
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.Shares of Exact Sciences Corporation (NASDAQ:EXAS) fell sharply in today's pre-market trading aft
Express News | Vanda Pharmaceuticals Shares Down 7.1% Premarket After Q1 Loss Vs Year-Ago Profit
Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
Comments
Future Pak's Strategic Move to Acquire Vanda Pharmaceuticals: A Comprehensive Analysis.
We found a bold and calculated maneuver, Future Pak LLC ("Future Pak") has stepped up its acquisition game by enhancing its offer for Vanda Pharmaceuticals Inc. ("Vanda" or "the Company"), signaling a pivotal moment in the pharmaceutical industry's mergers and acquisitions landscape. This revised proposal not only raises the cash consideration but notably...
We found a bold and calculated maneuver, Future Pak LLC ("Future Pak") has stepped up its acquisition game by enhancing its offer for Vanda Pharmaceuticals Inc. ("Vanda" or "the Company"), signaling a pivotal moment in the pharmaceutical industry's mergers and acquisitions landscape. This revised proposal not only raises the cash consideration but notably...
$Vanda Pharmaceuticals(VNDA.US$ Are you gonna go up for a bit more? Or will you fall like most of the market right now? Hehehe
$Vanda Pharmaceuticals(VNDA.US$ Benzinga· 7 mins ago
Future Pak Increases Bid For Vanda Pharmaceuticals To Include CVRs In Addition To $7.25-$7.75 Per Share In Cash; Offer Represents $11.62-$12.12 Per Share
Future Pak Increases Bid For Vanda Pharmaceuticals To Include CVRs In Addition To $7.25-$7.75 Per Share In Cash; Offer Represents $11.62-$12.12 Per Share
4
Read more